Related Experiment Video
Updated: Mar 13, 2026

Intralymphatic Immunotherapy and Vaccination in Mice
Published on: February 2, 2014
Case of Pediatric Bullous Systemic Lupus Erythematosus Treated with Intravenous Immunoglobulin
Margit Juhász1, Megan Rogge2, Mary Chen2
1Icahn School of Medicine at Mount Sinai, New York, New York.
Abstract:
This is a case report of a 16-year-old girl recently diagnosed with systemic lupus erythematosus (SLE) who presented with multiple blisters on the face, hands, arms, legs, trunk, and vaginal and oral mucosa. Skin biopsy was consistent with bullous SLE (BSLE). Dapsone is often the first-line treatment option for BSLE, but the patient's history of anemia and leukopenia and long-term immunosuppression requirement for her systemic symptoms raised concerns about dapsone and bone marrow toxicity, especially hemolytic anemia and agranulocytosis. She was started on intravenous immunoglobulin (IVIG), 2 g/kg divided over 3 days, with significant improvement in her cutaneous symptoms. IVIG is a treatment option for BSLE patients in whom agents such as dapsone are contraindicated.
Related Concept Videos
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Pharmacokinetics in Pediatric Patients: Drug Excretion
Nephrotic Syndrome III : Nursing Management

